Company intelligence / Profile preview
Xenova Ltd.
Reading, Berkshire, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
Xenova developed several clinical programs including a human papillomavirus vaccine (TA-CIN) that reached Phase 2, and addiction vaccines for nicotine and cocaine. Their lead cancer drug tariquidar was discontinued in 2003 due to toxicity concerns. TransMID for brain cancer was projected to potentially reach market by 2007.
- Therapeutic areas
- PsychiatryOncologyCardiovascular
- Modalities
- Small molecule drugsTherapeutic vaccinesGenetically engineered subunit vaccines
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Celtic Pharma
Beyond the preview
Go deeper on Xenova Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xenova Ltd..